Inside Wall Street: The Growing Interest in Achillion’s Hepatitis Drugs
At a liver disease conference in Boston, one highlight is expected to be reports from Achillion about its new hepatitis C treatments, especially ACH-1625. The buzz is growing that the little biotech is attracting the attention …